All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
On September 1, 2020, the U.S. Food and Drug Administration (FDA) approved the use of CC-486, oral azacitidine, for the maintenance of adult patients with acute myeloid leukemia (AML) in first remission after intensive induction chemotherapy, who are not able to complete intensive curative therapy. This includes patients in complete remission with incomplete hematological recovery.1
The approval was based on the results of the phase III QUAZAR AML-001 trial (previously reported on the AML Hub), which showed a clinically meaningful improvement in overall survival for patients > 55 years of age, treated with CC-486 plus best supportive care, compared to placebo (24.7 vs 14.8 months, respectively; p = 0.0009). 1
The convenient oral administration of this drug once daily makes it more appealing in this current climate, however, there are warnings that CC-486 should not be substituted for intravenous or subcutaneous azacitidine due to significant differences in pharmacokinetic properties.1
The FDA approval could see treatment with CC-486 become a standard component of AML therapy for adults in first complete remission who cannot proceed to intensive curative therapy.
Phase III QUAZAR AML-001 trial results
A summary of the QUAZAR AML-001 trial, as presented by Andrew Wei, The Alfred Hospital, Melbourne, AU, at the 61st ASH meeting in Orlando, US.
QUAZAR: Should maintenance with CC-486 become standard of care following induction chemotherapy?
The QUAZAR study investigated the use of CC-486 as maintenance therapy in patients with acute myeloid leukemia (AML) who are in first remission following...
Subscribe to get the best content related to AML delivered to your inbox